Immunotherapy Treatments: Who, When, and What to Know

Immunotherapy treatments are transforming cancer care, offering durable control and even long-term remission for many patients.

If you’re newly diagnosed or considering your next step after standard therapy, this guide explains who immunotherapy is for, when to explore it, the benefits and side effects to expect, and five cutting-edge options changing the game.

Who Are Immunotherapy Treatments For?

Many solid tumors and blood cancers respond to immunotherapy. The best-established uses include melanoma, non-small cell lung cancer, kidney (renal cell) cancer, bladder cancer, head and neck cancers, Hodgkin lymphoma, and certain colorectal and other tumors with mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H). In some settings, immunotherapy is used after surgery (adjuvant) or before surgery (neoadjuvant) to reduce recurrence risk.

Biomarkers can guide eligibility and expected benefit. Common markers include PD-L1 expression, MSI-H/dMMR status, and tumor mutational burden (TMB). High PD-L1 or the presence of MSI-H/dMMR often predicts stronger responses, but patients can benefit even when these markers are low or absent—especially when immunotherapy is combined with chemotherapy or targeted agents.

Not everyone is an ideal candidate right now. Caution is needed for people with active, severe autoimmune disease requiring immunosuppression, prior organ transplants (risk of rejection), uncontrolled infections, or poor functional status. Pregnancy also requires a specialized risk–benefit discussion.

When Should You Explore Immunotherapy?

At diagnosis of advanced disease

If your cancer is stage IV or has spread, ask about immunotherapy as a first-line option. In lung cancer, melanoma, kidney, bladder, and more, checkpoint inhibitors (like pembrolizumab, nivolumab, atezolizumab, and others) are frequently part of standard-of-care either alone or with chemotherapy.

Before or after surgery

For select cancers, immunotherapy given before surgery can shrink tumors and make procedures easier; given after surgery, it can reduce the chance of recurrence. Your team may reference “event-free” or “disease-free” survival data to help decide.

After standard treatments stop working

Many patients start immunotherapy after progression on chemotherapy, targeted therapy, or radiation. Even then, responses can be long-lasting in a subset of people.

Any time you’re eligible for a clinical trial

Don’t wait for a “last resort.” Clinical trials often provide access to the latest immunotherapy treatments and combinations earlier in care. Ask your oncologist or a major cancer center about trials that match your tumor type and biomarkers.

Key Benefits of Immunotherapy

• Durable responses: Some patients experience control that lasts years, even after stopping therapy.
• Survival improvement: In several cancers, immunotherapy increases overall survival compared with older standards.
• Tumor-agnostic approvals: Treatments for MSI-H/dMMR or TMB-high cancers offer options based on biology, not just tumor location.
• Organ-sparing potential: Responses can avoid or delay major surgery, radiation, or multi-agent chemotherapy in some cases.
• Quality-of-life advantages: While not side-effect free, many patients tolerate immunotherapy better than traditional chemotherapy.

Common Side Effects (5 to Know)

Because these drugs activate your immune system, side effects are often called “immune-related adverse events” (irAEs). They’re usually manageable if treated early—always report new symptoms promptly.

• Fatigue: The most common effect. Track energy levels, pace activities, and discuss labs to rule out anemia or thyroid issues.
• Skin rash or itching: Use fragrance-free moisturizers and sun protection; mild steroid creams or antihistamines may help.
• Diarrhea/colitis: New or worsening bowel changes can signal colon inflammation—call your team right away; steroids may be needed.
• Thyroid problems (hypo/hyperthyroidism): Can cause weight changes, fatigue, or anxiety; blood tests and hormone replacement often control symptoms.
• Lung inflammation (pneumonitis): New cough or shortness of breath is urgent; seek care promptly to prevent complications.

Other possible irAEs include hepatitis, adrenal or pituitary inflammation, joint pain, and infusion reactions. Early recognition is key.

5 New Immunotherapy Treatments Revolutionizing Cancer Care

1. Tumor-Infiltrating Lymphocyte (TIL) therapy
   In 2024, the first FDA-approved TIL therapy for melanoma demonstrated that expanding a patient’s own tumor-fighting T cells and reinfusing them can produce meaningful, sometimes durable responses after prior treatments. TIL therapy is being studied across other solid tumors.
2. Personalized mRNA neoantigen vaccines
   Custom vaccines designed from your tumor’s unique mutations “teach” the immune system what to attack. Early studies—in combination with PD-1 inhibitors—have shown promising reductions in recurrence risk in melanoma, with trials expanding to lung and other cancers.
3. Next-generation checkpoints: LAG-3 and beyond
   Pairing PD-1/PD-L1 inhibitors with LAG-3 blockade has improved outcomes in melanoma, and agents targeting TIGIT and other checkpoints are in advanced trials. These combinations aim to overcome resistance to single-agent therapy.
4. Bispecific T-cell engagers (BiTEs) and antibodies
   These drugs bring T cells into direct contact with cancer cells. Several are approved in blood cancers (for example, BCMA- or CD20-targeted bispecifics) and are rapidly moving into earlier lines of therapy and new tumor types.
5. Off-the-shelf cell therapies (allogeneic CAR-T/CAR-NK)
   Unlike personalized autologous CAR-T, allogeneic approaches use donor cells, enabling faster treatment start and broader access. Early trials show activity with improving safety profiles, and NK-cell engagers are also gaining momentum.

Availability varies by country and indication. Ask your oncologist about approvals, access programs, or relevant clinical trials.

How to Get Started: A Step-by-Step Plan

• Confirm your diagnosis and stage: Obtain pathology reports and imaging summaries.
• Request biomarker testing: PD-L1, MSI/dMMR, TMB, and other relevant markers can open immunotherapy paths.
• Discuss fit and timing: Review your autoimmune history, transplant status, medications (including steroids), and goals.
• Evaluate options: Monotherapy vs. combination, adjuvant/neoadjuvant vs. metastatic settings, and trial eligibility.
• Plan for side-effect monitoring: Set up early lab checks, symptom diaries, and clear contact instructions for urgent issues.
• Address logistics: Insurance authorization, financial assistance, travel support, and infusion scheduling.
• Seek a second opinion: Especially for rare cancers or complex decisions—major centers may offer additional options.

Frequently Asked Questions

How long does immunotherapy last?

Many protocols treat for up to two years if tolerated and effective, though duration varies. Some patients stop earlier due to side effects or sustained response.

Can I get vaccines while on immunotherapy?

Inactivated vaccines (like flu shots) are generally considered acceptable; live vaccines are typically avoided. Always confirm with your oncology team.

Will I feel well enough to work or travel?

Many people continue normal activities with adjustments. Plan around infusion days, track fatigue, and keep emergency contact info handy when traveling.

Bottom line: Immunotherapy treatments have reshaped cancer care, offering longer survival and, for some, lasting remission. With the right timing, biomarkers, and monitoring, you and your care team can decide if, when, and how to integrate these powerful therapies into your plan.